Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study
- PMID: 12089368
- DOI: 10.1097/01.asn.0000018407.60002.b9
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study
Abstract
This study sought to investigate the cardiac and renal effects of rigorous versus standard BP control on autosomal-dominant polycystic kidney disease (ADPKD). A prospective, randomized, 7-yr study was performed to examine the effect of rigorous (<120/80 mmHg) versus standard (135-140/85-90 mmHg) BP control on left ventricular mass index (LVMI) and kidney function in 75 hypertensive ADPKD patients with left ventricular hypertrophy. LVMI was measured by echocardiogram at baseline and at 1 and 7 yr. Renal function was assessed by measuring serum creatinine and 24-h creatinine clearance every 6 mo for 3 yr, then annually for an additional 4 yr. The baseline characteristics were comparable in the two groups. During the study, average mean arterial pressure was 90 +/- 5 mmHg for the rigorous group and 101 +/- 4 mmHg for the standard group (P < 0.0001). The LVMI decreased by 21% in the standard group and by 35% in the rigorous group. A mixed model longitudinal data analysis revealed that rigorous BP control was significantly more effective in decreasing LVMI (P < 0.01). There was no statistically significant difference in renal function between the two groups. In conclusion, left ventricular hypertrophy, a major cardiovascular risk factor, was decreased to a significantly greater extent by rigorous than standard BP control. This finding has particular clinical importance because cardiovascular complications are the most common cause of death in ADPKD patients.
Similar articles
-
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.Nephrol Dial Transplant. 2008 Feb;23(2):573-9. doi: 10.1093/ndt/gfm731. Epub 2007 Nov 4. Nephrol Dial Transplant. 2008. PMID: 17984104 Clinical Trial.
-
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.Nephrol Dial Transplant. 1999 May;14(5):1113-6. doi: 10.1093/ndt/14.5.1113. Nephrol Dial Transplant. 1999. PMID: 10344347 Clinical Trial.
-
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.Am J Kidney Dis. 2000 Mar;35(3):427-32. doi: 10.1016/s0272-6386(00)70195-8. Am J Kidney Dis. 2000. PMID: 10692268 Clinical Trial.
-
Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.J Am Soc Nephrol. 2009 Sep;20(9):1888-93. doi: 10.1681/ASN.2008080882. Epub 2009 Aug 20. J Am Soc Nephrol. 2009. PMID: 19696226 Review.
-
Cardiovascular complications in autosomal dominant polycystic kidney disease.Curr Hypertens Rev. 2013 Feb;9(1):2-11. doi: 10.2174/1573402111309010002. Curr Hypertens Rev. 2013. PMID: 23971638 Review.
Cited by
-
A Systematic Review of Reported Outcomes in ADPKD Studies.Kidney Int Rep. 2022 Jul 5;7(9):1964-1979. doi: 10.1016/j.ekir.2022.06.012. eCollection 2022 Sep. Kidney Int Rep. 2022. PMID: 36090492 Free PMC article.
-
Geographic differences in the increasing ESRD rate have disappeared in Japan.Clin Exp Nephrol. 2011 Oct;15(5):708-713. doi: 10.1007/s10157-011-0466-5. Epub 2011 Jun 3. Clin Exp Nephrol. 2011. PMID: 21638004
-
Decade in review--polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease.Nat Rev Nephrol. 2015 Nov;11(11):638-9. doi: 10.1038/nrneph.2015.164. Epub 2015 Oct 13. Nat Rev Nephrol. 2015. PMID: 26460355 No abstract available.
-
Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.JAMA Intern Med. 2017 Oct 1;177(10):1498-1505. doi: 10.1001/jamainternmed.2017.4377. JAMA Intern Med. 2017. PMID: 28873137 Free PMC article.
-
Early renal abnormalities in autosomal dominant polycystic kidney disease.Clin J Am Soc Nephrol. 2010 Jun;5(6):1091-8. doi: 10.2215/CJN.00360110. Epub 2010 Apr 22. Clin J Am Soc Nephrol. 2010. PMID: 20413443 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical